HOME >> MEDICINE >> NEWS
New data on the effect of Atacand(R) on NYHA class in a broad spectrum of heart failure patients

Mlndal, Sweden, 9 March 2004 Data presented today at the American College of Cardiology (ACC) annual meeting add weight to the evidence shown in the original publications from the CHARM* Programme of the effects of Atacand (candesartan cilexetil) in chronic heart failure (CHF) patients. The results from further analysis of the data add further support for the CHARM study as a landmark clinical research programme.

Importantly, one analysis1 found that New York Heart Association (NYHA) functional class improved in a broad spectrum of CHF patients treated with Atacand. Of all CHARM patients, 35.4% taking Atacand improved in NYHA functional class, 55.6% remained unchanged and 9% worsened. This compared with 32.5%, 57.5% and 10.3% respectively in the placebo group (p=0.004). These findings were supported by a favourable change in the Overall Treatment Evaluation in the Atacand group compared to the placebo group (p=0.01).

Commenting on this additional analysis, Professor John McMurray, principal investigator in the CHARM-Added study, Glasgow University and Western Infirmary, Glasgow, Scotland, said "Improving symptomatic well-being is a key objective of heart failure treatment. NYHA functional classification is the most widely used and validated measure of symptomatic limitation in CHF. That candesartan has been shown to improve NYHA functional class across the broad spectrum of CHF investigated in the CHARM Programme will have significant implications for clinical practice. These findings are consistent with a reduction in CHF hospitalisations".

A further analysis suggests that the development of atrial fibrillation (AF) in some patients with symptomatic chronic heart failure may also be reduced. Of the 7,601 heart failure patients in CHARM, 72.6% did not have atrial fibrillation (AF) at baseline. This new analysis found that, in the patients randomised to Atacand, new incidence of AF during the trial was 6.5%, compared to 7.9% in the place
'"/>

Contact: Mark Chamberlain
mark.chamberlain@ketchum.com
44-207-611-3649
Ketchum
9-Mar-2004


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. Study shows patch therapy may be as effective as oral medications
3. Chronic pain treatments more effective when taken together, new study shows
4. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
5. Brain activity prior to treatment flags vulnerability to antidepressant side effects
6. Improving access to healthy food has little effect on diet
7. Storage time and temperature effects nutrients in spinach
8. Costs of antidepressants could have funded effective alternatives
9. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
10. Government wasting your taxpayer money on ineffective drug cure
11. Neurobehavioral function during coma, stroke rehabilitation effective for elderly

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2016)... ... , ... For more than fifty years, we've suffered whiplash as each new scientific study seemed ... the latest nutritional advice – advice that was supposed to keep us healthy and slim. ... American adults are considered to be overweight and more than 1 in 3 adults are ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users ... footage," said Christina Austin - CEO of Pixel Film Studios. , With the ... easily add stylish color grades to their footage. A LUT is a Lookup Table ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State College of Optometry ... work on visual evoked potential and human attention. The article, VEP and Human ... Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., Pine Brook, NJ) ...
(Date:5/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... as the Medical Director of its new DeSoto facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Stern Environmental ... will be selling the device branded as Stern’s Real Time Monitoring (RTM) ... bedbugs to the hotel and motel industry, colleges for use in dormitories, shelters, and ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Mass. , May 24, 2016  NxStage Medical, ... technology company focused on advancing renal care, today announced ... plans to participate in the following schedule of investor ... be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, June ...
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
(Date:5/24/2016)... 24, 2016 Open Access Journal ... Neurophysiology  Elsevier , a world-leading provider ... today announced the launch of Clinical Neurophysiology ... that focuses on clinical practice issues in clinical neurophysiology. ... series, normal values and didactic reviews. It is an ...
Breaking Medicine Technology:
Cached News: